How Will the Market React to Agenus Inc (AGEN) Stock Getting a Bullish Rating

The market has been high on Agenus Inc (AGEN) stock recently. AGEN gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Agenus Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on AGEN!

See Full AGEN Report

What is Stock Sentiment?

When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment. Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish. InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion. For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.

What's Happening With AGEN Stock Today?

Agenus Inc (AGEN) stock is up 0.08% while the S&P 500 is down -0.31% as of 11:35 AM on Friday, Sep 10. AGEN is up $0.01 from the previous closing price of $6.54 on volume of 1,028,649 shares. Over the past year the S&P 500 has gained 31.79% while AGEN is up 56.32%. AGEN lost -$1.12 per share in the over the last 12 months. To see InvestorsObserver's Sentiment Score for Agenus Inc click here.

More About Agenus Inc

Agenus Inc is an American biotechnology company. Its main target is immuno-oncology treatments. The company's portfolio consists of therapeutic antibodies and vaccines to treat immuno-oncology illnesses: cancers, shingles, malaria, glioblastoma, and others. Agenus treatments aim, by combining multiple antibody platforms, to stimulate the immune system to recognize and fight cancer cells. The company has been cooperating with companies like Incyte, Merck Sharpe & Dohme, and Recepta Biopharma to achieve over a dozen antibody programs. Some of its products include Prophage, AutoSynVax, QS-21 Stimulon, and others. Click Here to get the full Stock Report for Agenus Inc stock.